Friday 6 November 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.

Revenue: +36.3%
EPS: +36.0%
Free cash flow: +3.85%
Total debt: −26.6%

Quarter to September 2026, against a year earlier

907.85 4.95 +0.55%

Follow REGN

Alert me

Market cap: $93.4B
P/E: 19.2×
Fwd P/E: 19.2×
Dividend yield: 0.41%
F-score: 5/9
Altman Z: 7.49
Beneish M: −2.53
Dividend safety: 77/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Regeneron Pharmaceuticals, Inc. (REGN) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2020: revenue by products and services, and margins
Net product sales	5,568	65.52%
Sanofi Collaboration Revenue	1,186	13.96%
Collaboration revenue	1,186	13.96%
Other revenue	557	6.56%
Gross margin		86.82%
Operating margin		42.09%
Pre-tax margin		44.84%

Revenue by product or service $m

Line	FY2020
Net product sales	5,568 65.52%
Sanofi Collaboration Revenue	1,186 13.96%
Collaboration revenue	1,186 13.96%
Other revenue	557 6.56%
Revenue	8,497

Gross profit by product or service $m, and margin

	FY2020
Cost of collaboration and contract manufacturing	‡
Net product sales	‡
Gross profit	‡
	‡
	‡
	‡
	‡
	‡
	‡
	‡
	‡
	‡

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Product candidates in clinical development	Q3 FY2026	50.00	45.00	+11.11%

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024
Product candidates in clinical development	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.